-
Ensifentrine for Cystic Fibrosis Enters Phase 2 Trial
The World Health Organization has given RPL554 the identifying name ensifentrine. Ensifentrine is a potential inhaled therapy for cystic fibrosis developed by Verona Pharma, and it is now in a Phase 2 clinical trial. Click here to learn more about it.
Are you interested in following news about this potential therapy for CF?
Sorry, there were no replies found.
Log in to reply.